Neurogene Inc. Announces Results of 2026 Annual Meeting of Stockholders
New York, June 4, 2026 – Neurogene Inc. (NASDAQ: NGNE), a clinical-stage biotechnology company focused on the development of genetic medicines for neurological diseases, has released the results of its 2026 Annual Meeting of Stockholders, which took place on June 3, 2026.
Key Points from the Annual Meeting
- Quorum Achieved: A total of 11,387,407 shares of common stock were present in person or by proxy, representing approximately 72.92% of the voting power of shares entitled to vote. This enabled the valid transaction of business at the meeting.
- Board Elections: Stockholders elected two Class III directors—Dr. Robert Baffi and Mr. Rohan Palekar—to the Board of Directors. Both will serve terms lasting until the 2029 annual meeting and until their successors are duly elected and qualified.
- Robert Baffi: 9,540,734 votes for; 548,736 votes withheld; 1,297,937 broker non-votes.
- Rohan Palekar: 9,540,734 votes for; 548,736 votes withheld; 1,297,937 broker non-votes.
- Executive Compensation: The advisory (non-binding) vote to approve the compensation of named executive officers was passed:
- 9,991,445 shares voted for
- 36,394 against
- 61,631 abstaining
- 1,297,937 broker non-votes
- Independent Auditor Ratification: Stockholders ratified, on a non-binding basis, the appointment of Deloitte & Touche LLP as Neurogene’s independent registered public accounting firm for the fiscal year ending December 31, 2026:
- 9,345,925 shares for
- 1,939,039 against
- 102,443 abstained
- Frequency of Advisory Vote on Executive Compensation: The majority of shareholders voted to hold future non-binding advisory votes on executive compensation annually:
- 10,006,265 shares for annual voting
- 3,407 for every two years
- 80,798 for every three years
- 1,297,937 broker non-votes
As a result, Neurogene will continue to hold annual advisory votes on executive compensation until the next required vote on frequency, or unless the Board decides otherwise.
Key Takeaways and Potential Share Price Impact
- No Board Changes or Shareholder Activism: The election of directors proceeded without contest or significant opposition. This signals stability in board leadership, which may be viewed positively by investors seeking continuity.
- Strong Support for Executive Compensation: The overwhelming approval of executive compensation suggests alignment between management and stockholder interests, which can be a positive indicator for governance-focused investors.
- Auditor Ratification: There was a notable minority (1.94 million votes) against the ratification of Deloitte & Touche LLP as the auditor, which may warrant further scrutiny by investors interested in governance and financial oversight. However, the ratification did pass by a wide margin.
- Annual Say-on-Pay Confirmed: Investors will continue to have yearly input on executive pay practices, reflecting best practices in corporate governance.
Other Important Information for Shareholders
- Company Details: Neurogene Inc. is incorporated in Delaware, headquartered at 535 W 24th Street, 5th Floor, New York, NY 10011. The company’s common stock is listed on The Nasdaq Global Market under the symbol “NGNE”.
- Emerging Growth Company Status: Neurogene is not classified as an emerging growth company, indicating it is subject to the full reporting requirements and governance standards applicable to mature public companies.
Conclusion
The 2026 Annual Meeting results reinforce the current leadership and governance framework at Neurogene Inc., with a clear mandate from shareholders on board composition, executive compensation, and financial oversight. There were no new initiatives or surprise proposals, and the company continues its current course. Investors may view this as a signal of stability, though the notable votes against auditor ratification could merit monitoring for future developments.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult with a financial advisor before making investment decisions. The information is based on public filings and may not reflect all developments or more recent events affecting Neurogene Inc.
